MELBOURNE, AUSTRALIA--(Nov 29, 2016) - Genetic Technologies Limited ( ASX : GTG ) ( NASDAQ : GENE ) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.

 

The core technology behind this CRC risk assessment test was developed by Professor Mark Jenkins and his research team at the University's Centre for Epidemiology and Biostatistics.

SAN FRANCISCO, Oct. 19, 2016  -- iRhythm Technologies, Inc., a leading digital health care solutions company focused on the advancement of cardiac care, today announced the pricing of its initial public offering of 6,294,118 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts.  In addition, iRhythm has granted the underwriters a 30-day option to purchase up to an additional 944,117 shares of common stock at the same price solely to cover over-allotments, if any. The company's shares are expected to begin trading on NASDAQ on October 20, 2016 under the ticker symbol "IRTC."

 

The offering is expected to close on October 25, 2016, subject to satisfaction of customary closing conditions.

 

J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering.  Canaccord Genuity and BTIG are acting as co-managers.

HASBROUCK HEIGHTS, N.J., Aug. 24, 2016 -- Nymox Pharmaceutical Corporation (NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer. The aim of the study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In the new study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients' discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed. Results have now shown that there was 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).

MEDFORD, N.Y., Aug. 25, 2016  -- Chembio Diagnostics, Inc. (CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has been awarded a contract for up to $13.2 million in total funding from the U.S. Department of Health and Human Services (HHS); Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) for the development and commercialization of the Company’s rapid POC Zika test and Zika-related products.

 

The award includes an initial commitment of $5.9 million allocated specifically to the DPP®Zika IgM/IgG Assay and DPP® Micro Reader, as well as an option for an additional $7.3 million to fund the development, clinical trial and regulatory submissions related to the Company’s DPP® Zika/Chikungunya/Dengue IgM/IgG Combination Assay.